Interim CFO Potashnick buys 212.5K shares at $0.40; cluster of 5 other insider buys in 14 days as stock trades -59.9% from 52-week high.
Interim CFO Robert Potashnick purchased 212,500 shares at $0.40 on 2026-02-12, representing a new position at a price 42.0% below the current price of $0.69 and 76.7% below the 52-week high of $1.72. The transaction occurs within a 14-day cluster in which 5 other insiders also executed purchases, suggesting coordinated or coincident confidence among multiple executives. Envoy Medical faces material headwinds: the company posted $-6,482,000.00 net income in its most recent fiscal year, reported only $42,000.00 in latest-quarter revenue, and experienced -28.8% annual revenue decline year-over-year, with a $19,862,692.59 market cap. The concurrent buying by Potashnick and peers against a backdrop of significant operating losses and revenue contraction warrants investor scrutiny of whether purchases reflect conviction in turnaround momentum or whether planned operational initiatives support renewed execution.